title: "Watch-and-see" policy for the clinically positive neck in head and neck cancer treated with chemoradiotherapy.
abstract: BACKGROUND
  Chemoradiotherapy (CRT) is becoming more widely used for head and neck cancer. However, there are conflicting theories regarding the best management options for patients with advanced nodal disease.
  
  
  METHODS
  From 1990 to 1999, we treated 96 patients with N1-N2 neck disease by concomitant CRT for organ preservation, using weekly carboplatin or a low daily dose of cisplatin, followed by a "watch-and-see" policy for the neck. In the present study, we retrospectively analyzed the treatment outcome in 63 of these patients who received definitive CRT for primary and neck diseases and were monitored for neck disease for more than 2 years.
  
  
  RESULTS
  In 12 of the 22 (55%) N1 patients, CRT successfully controlled the neck disease. CRT was successful in 18 of the 41 (44%) patients with N2 disease. In 6 (60%) of 10 patients with residual or recurrent N1 disease, salvage surgery was successful. Of the 23 patients with residual or recurrent N2 disease, salvage surgery was successful in 8 patients (35%). The group of patients who showed a clinical complete response (CCR) to CRT had an overall survival rate of 62.4% (33 patients), whereas for those with a less than complete response (<CCR), the figure was 13.3% (30 patients; P < 0.001). Among the <CCR-neck group, patients who underwent neck dissection (ND) as well (n = 20) did not have a significantly better overall survival than those who did not undergo ND (n = 10; P = 0.069).
  
  
  CONCLUSIONS
  We propose a treatment plan for neck disease that involves observing the neck closely following CRT. ND should be planned only when there is evidence that neck disease exists.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan. ak-homma@med.hokudai.ac.jp
authors.forename: Akihiro
authors.initials: A
authors.lastname: Homma
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Furuta
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Oridate
authors.forename: Fumiyuki
authors.initials: F
authors.lastname: Suzuki
authors.forename: Eisaku
authors.initials: E
authors.lastname: Higuchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nishioka
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shirato
authors.forename: Tatsumi
authors.initials: T
authors.lastname: Nagahashi
authors.forename: Katsunori
authors.initials: K
authors.lastname: Yagi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fukuda
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D037981:Neck Dissection; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin